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Abstract
Objectives Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs)
are widely used in the treatment of inflammation and pain.Most effects of NSAIDs
are attributed to the inhibition of cyclooxygenases (COX). However, many NSAIDs
may have other effects not related to COX, including the modulation of various
ion channels. The clinical implications of the effects on channels are not fully
understood. This review outlines the effects of NSAIDs, with special attention to
diclofenac, on ion channels and highlights the possible underlying mechanisms.
Key findings NSAIDs have effects on channels such as inhibition, activation or
changes in expression patterns. The channels affected include voltage-gated Na+,
Ca2+, orK+ channels, ligand-gatedK+ channels, transient receptor potential andother
cation channels aswell as chloride channels in several types of cells.Themechanisms
of drug actions not related to COX inhibition may involve drug–channel interac-
tions, interference with the generation of second messengers, changes in channel
expression, or synergistic/antagonist interactions with other channel modulators.
Summary The effects on ion channels may account for novel therapeutic actions
of NSAIDs or for adverse effects.Among theNSAIDs, diclofenacmay serve as a tem-
plate for developing new channel modulators and as a tool for investigating the
actions of other drugs.
Introduction
Anti-inflammatory action and
cyclooxygenase inhibition
Non-steroidal anti-inflammatory drugs (NSAIDs) are among
the most commonly prescribed agents for analgesic, anti-
pyretic and anti-inflammatory purposes, with many of the
drugs being readily available over-the-counter. They include
such various substances as salicylates (aspirin), aryl propi-
onic derivatives like ibuprofen, aryl acetic derivatives like
diclofenac, indole derivatives like indometacin, oxicams like
piroxicam, melusid, phenylbutazone, etc. As initially pro-
posed by Vane[1], these structurally diverse chemicals have in
common the fact that they inhibit cyclooxygenase (COX)
enzymes,which catalyse the conversion of arachidonic acid to
prostaglandin (PG) G2 and eventually to PGH2, a precursor
of thromboxane A2 and other effector prostaglandins (for
reviews see Botting[2] and Vane et al.[3]). At least two distinct
isoforms of COX are known to exist: the constitutive COX-1
found in platelets, kidneys, gut and other tissues, and the
inducible COX-2 produced locally in response to inflamma-
tory signals, growth factors, cytokines, oncogenes and other
stress signals.[4,5] The existence of different COX isoforms
has stimulated the development of new isoform-selective
NSAIDs. However, most of the drugs commonly used in the
therapy are COX nonselective (i.e. they inhibit both COX-1
and COX-2).
Other actions of NSAIDs: COX and
other effectors
Besides their use in pathological processes related to inflam-
mation,NSAIDs have been proposed for use in treating other
disease processes. For example, low-dose aspirin is widely
used for its anti-platelet aggregation effect, due to its inhibi-
tion of COX.[6] NSAIDs have also been suggested to exert ben-
eficial effects in cancer and in neurodegenerative disorders
such as Alzheimer’s disease.[7–9] The anticarcinogenic effect
may involve an inhibition of tumour growth, a reduction of
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metastases, or an improved response to treatment by other
antitumour agents.Themechanismsunderlying these antitu-
mour effects are complex and largely unknown. Some, but
not all anticancer effects may be related to the expression of
COX-2 in cancer cells and include such various processes as
themodification of the expression level of proteins associated
with apoptosis or the suppression of an upregulation of the
multidrug resistance-associated proteins.[10,11]
With the increased use of the nonselective NSAIDs
like indometacin, naproxen and ibuprofen, life-threatening
adverse effects such as gastrointestinal mucosal erosion/
perforation, renal impairment and platelet dysfunction also
became common.[12,13] These adverse effects, particularly
gastrointestinal toxicity, have been attributed to the loss
of physiological PGs due to inhibition of COX-1 and
not COX-2, and clinically COX-2-selective drugs such as
rofecoxib and lumiracoxib show substantially lower inci-
dences of gastric ulceration compared with naproxen or
ibuprofen.[14–17] It is therefore understandable that there had
been a general trend towards marketing COX-2-selective
NSAIDs.However, these drugs also have adverse effects.
A promising COX-2 selective NSAID rofecoxib was shown
to be associated with an increased risk of myocardial infarc-
tion and cerebrovascular thrombo-embolic accidents in a
multicentre trial, a finding that was supported by other
studies and which led to the withdrawal of the drug from the
market in 2004.[18–20] The following year, a related drug, valde-
coxib, was also withdrawn. The COX-2-selective drug cele-
coxib remains in use, but it has been reported to be associated
with cardiovascular risk.[21,22] The basis of these adverse
effects is unclear, but COX-2-selective drugs have been
proposed to promote atherogenesis by interfering with the
metabolism of low density lipoproteins and of vascular cell
membrane phospholipids, or by creating an imbalance
between endothelial COX-2-dependent prostacyclin (PGI2)
and platelet COX-1-dependent thromboxane A2 (see Joshi et
al.[23] and Capone et al.[24]). There is now therefore less drive
towards COX-2-selective drugs, making it likely that nonse-
lective NSAIDs with relatively less gastrointestinal toxicity
may retain clinical prominence.[25,26] However, the increased
risk for cardio- and cerebrovascular events is not specific for
COX-2-selective inhibitors but also concerns nonselective
NSAIDs.
Besides COX inhibition, the mechanisms underlying
various potential therapeutic or adverse effects of NSAIDs
remain unclear. Several NSAIDs have been shown to
modulate ion channels, and there is a possibility that these
effects on ion channels could account for the drug actions
not directly linked to COX inhibition. Among the effects
of NSAIDs on ion channels, those of diclofenac have
been the most extensively studied. Diclofenac (2-[2-(2,6-
dichlorophenyl)aminophenyl]acetic acid) has structural
components similar to those found in other NSAIDs and in
functionally different compounds such as diphenhydramine
or carbamazepine (see Figure 1a for chemical structures).
Diclofenac has been in clinical use as an anti-inflammatory
agent for over three decades, and has been proposed to have
other beneficial effects like central analgesia and anticancer
activity.[27–29] Besides the typical NSAID-related adverse
effects, diclofenac is also implicated in hepatic and renal tox-
icity as well as in increased cardiovascular risk.[19,20,30–32] This
article outlines the effects of diclofenac and other NSAIDs on
ion channels and highlights the possible mechanisms under-
lying the drug actions. Some new experimental data from
studies on cardiac myocytes have been presented.
Effects of diclofenac and other
NSAIDs on ion channels
Asmentioned above,manymembers of theNSAID group are
reported to exert effects on ion channels in various native
tissues or cells and in expression systems. Some NSAIDs are
even frequently used as pharmacological tools to identify ion
currents due to particular classes of channels (e.g. fenamates,
used to identify anion channels).Most of these effects on ion
channels occur at concentrations much higher than those
known to inhibit COX, and so it can be assumed that the
actions on channels are nonspecific and of little relevance to
clinical conditions. However, in-vivo concentrations of some
NSAIDs may reach millimolar levels, making ion channel
effects potential contributors to therapeutic effects. In addi-
tion, based on the demonstrated beneficial effects of NSAIDs
in animal models in which COX has been suppressed, or on
the evidence for pharmacological effects of NSAID-related
drugs not known to have action on COX, as well as on the
heterogeneity of effects among NSAIDs, there is increasing
awareness of the possible role of non-COX targets (such as
ion channels) as potential players in the beneficial effects of
NSAIDs.
The effect of NSAIDs on ion channels are not selective,
since practically all those found to act on channels affect
many channel types. Among NSAIDs, salicylic acid has been
reported to modulate such diverse channels as voltage-
dependentNa+, K+ or Ca2+ channels (described below), as well
as channels associated with the GABAA, glycine and NMDA
receptors.[33–35] Recent studies indicated that the drug inhib-
ited acid-sensing ion channels.[36] Fenamates, which include
the clinically used niflumic acid, are known to inhibit various
Cl--selective channels, but they are also used to inhibit many
cation-nonselective channels. In addition, they may show
inhibitory effects on HCN channels or stimulatory effects on
other channels, including K+ channels.[37,38]
The basis for this pleiotropic action on channels remains
unclear. One mechanism could implicate an indirect action
by interfering with COX, resulting in the elimination of the
effects of COX products or in the enhancement of the effects
Diclofenac and ion channels Asfree Gwanyanya et al.
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of endogenous arachidonic acid (Figure 2). However, as
discussed below, many effects on channels are due to a direct
action on the channel proteins. These direct effects may
involve a modification of channel gating properties, an
effect on pore permeation, or a change in channel protein
expression (Figure 2).Nonetheless,many channels are insen-
sitive to NSAIDs, whereas the effects on others are still yet to
be evaluated.
The channels affected by NSAIDs include voltage-gated
Na+, voltage-gated L-type Ca2+, voltage- and ligand-gated K+,
transient receptor potential (TRP), andothers (seeTable 1 for
a summary of diclofenac effects).
Voltage-gated Na+ channels
Voltage-gated Na+ (NaV) channels underlie the initial depo-
larization phase of the action potential in many excitable
cells, and modulation of these channels constitutes the basis
for the treatment of pain and of hyperexcitability conditions
such as epilepsy or cardiac arrhythmias.Asmentioned above,
part of these therapeutic actions may be due to COX inhibi-
tion. For example, flufenamic acid and indometacin suppress
the increase of INa caused by intracellular PGs produced fol-
lowing cell dialysis with arachidonic acid.[61] But other effects
involve a direct interaction with the channel protein.
Indometacin, aspirin or antipyrin did not change INa in
dorsal root ganglion (DRG) neurons nor did nepafenac and
amfenac change the current in trigeminal ganglion neu-
rons.[39,42] Aspirin also has no effect on NaV channels in
mice spinal ganglion neurons.[35] However, in rat pyramidal
neurons, the aspirin metabolite salicylate inhibited INa by
shifting the steady-state inactivation to more negative poten-
tials.[62] Ibuprofen or the COX-2 selective inhibitor NS 398
decreased the inflammation-induced upregulation of NaV 1.7
channels in DRG neurons.[63] This effect was indirect since it
was related to the suppression of PG formation. Another
COX-2 selective inhibitor, celecoxib, also decreased the
expression of tetrodotoxin (TTX)-resistantNaV channels (i.e.
channels displaying low sensitivity to TTX) in similar types
of cells.[64]
Electrophysiological effects of diclofenac have been most
extensively characterized on voltage-gated Na+ (NaV) chan-
nels. The drug decreases the peak amplitude of currents
carried by several types of NaV channels in various cells,
without changing activation kinetics or ion selectivity (as
indicated by the lack of change of the reversal potential). The
affected NaV channels include TTX-sensitive channels in
DRG neurons and in myoblasts as well as TTX-resistant
channels in DRG neurons.[39,40] The drug also blocks Na+
channels in brain CA1 region neurons and in trigeminal
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Figure 1 Diclofenac and related drugs: suppression of the voltage-gated Na+ current in cardiac myocytes. (a) Chemical structures of diclofenac
and other drugs. Notice (1) the anthranilic acid moiety in its derivatives N-(p-amylcinnamoyl)anthranilic acid (ACA) and flufenamic acid, but a modified
structure in diclofenac. (2) Diclofenac, ibuprofen, and anthranilic acid and anthranilic acid derivatives contain a carboxylate (COOH) group.
(3) Diclofenac, flufenamic acid, diphenhydramine, carbamazepine and phenytoin contain a diphenyl group. (b) Original traces of Na+ currents (INa)
from patch clamp recordings in a pig ventricular myocyte. Currents were obtained using ramps in a cell dialysed and superfused with K+-free solutions
containing physiological levels of Na+. Diclofenac (100 mM), flufenamic acid (100 mM), and ACA (20 mM) were applied extracellularly and separately.
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ganglion neurons.[41,42,65] The effect of diclofenac on Na+
channels in nervous tissue is reversible. In DRG neurons,
the potency to block TTX-sensitive Na+ currents (INa)
(Kd = 14 mm) appeared higher than for TTX-resistant INa
(Kd = 97 mm).[39]
The effect on peak current amplitude in brain CA1 region
neurons depends on the holding membrane potential before
depolarization: it is absent if the holding potential is very
negative, but it increases with more depolarized holding
potentials.[41,65] This indicates that the effect of diclofenac is
channel state dependent. The lack of an effect with very
negative holding potentials suggests that the drug has little
affinity for the resting state, whereas the decrease of peak
current with less negative holding potentials and the use-
dependent suppression of INa indicate an interaction with
the inactivated and/or the activated channel states.[41,65] The
binding to the inactivated state of the channel is reflected by
a shift of the inactivation curve to hyperpolarized poten-
tials.[39,41] The affinity for the inactivated state of the channel
(Kinactive = 7 mm), obtained from the magnitude of the shifts
in steady-state voltage-dependent inactivation (or availabil-
ity) curves, is at least two-orders of magnitude higher com-
pared with the affinity for the resting state (Kresting = 880–
1500 mm).[41] An interaction with the open state is suggested
by the slowing of Na+ current decay in the presence of
diclofenac. It can be further demonstrated by a voltage-
dependent increase in current amplitude when inactivation
is suppressed in Na+ channel mutants expressed in heterolo-
gous systems. In these inactivation-deficient mutants, the
inhibitory effect of diclofenac is lost, and instead the drug
actually enhances INa, suggesting a stabilization of the open
state of the channel.[41] The drug has been proposed to
induce allosteric changes via a binding site in the ion con-
ducting pathway accessible from outside the cell, since the
blocking effects are modulated by extracellular, but not by
internal Na+.[41]
The above effects of diclofenac on Na+ channels are not
surprising given that it contains a diphenyl structure similar
to the one present in other drugs, such as carbamazepine,
phenytoin and lamotrigine, which also act on Na+ channels.
Diclofenac and carbamazepine seem to share a common
binding site, since their effects are mutually exclusive.[41]
However, there are also differences between these two drugs:
whereas both drugs also bind to the open state, carbam-
azepine causes an open state channel block in the presence of
extracellular Na+ (resulting in an accelerated decay of the
macroscopicNa+ current), in contrast to diclofenac,which, as
discussed above, stabilizes the open state and causes a slight
slowing of macroscopic current decay.[41]
Due to the failure of some NSAIDs to inhibit INa, the
suppressive effects of diclofenac in neurons appear to take
place independently of COX inhibition. This finding suggests
that although COX inhibition is an essential component
of NSAID effect, COX-independent effects such as the
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Figure 2 Cellular actions of non-steroidal anti-inflammatory drugs on ion channels. Cyclooxygenase (COX)-dependent and COX-independent path-
ways of actions of non-steroidal anti-inflammatory drugs (NSAIDs) on cell membrane ion channels. The cascades of interactions are indicated by bold and
dotted lines. NSAIDs act on ion channels directly or indirectly, via intracellular molecules. Cross-talk between the two pathways may also occur.
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inhibition of INa could contribute to the known antinocicep-
tive effects of some NSAIDs.[66,67]
In myoblasts, diclofenac also shows a greater block of
TTX-sensitive INa at less negative potentials and shifts the
inactivation curve to more negative potentials.[40] Unlike in
the above-mentioned CA1 region neurons, diclofenac also
inhibits INa in myoblasts when applied from the intracellular
compartment.[40] Furthermore, the blocking effects of the
drug applied from inside and outside the cell are additive,
suggesting the presence of distinct drug binding sites.
Here also, the effect of extracellular diclofenac exhibits a
frequency-dependence as in neurons. To account for the
frequency-dependency of the block, the authors proposed
that there was a fast binding of the drug to the channel, fol-
lowed by a slow unbinding process, as is described for local
anaesthetics (see Butterworth et al.[68]).[40] However, other
factors may play a role given the presence of other complex
effects such as the spontaneous partial recovery from the
block observed in the same cells.[40]
The effects of diclofenac and of other NSAIDs in cardiac
cells have so far received little attention despite the potential
cardiovascular side effects of the drugs. A reversible block of
INa by diclofenac, but not by other COX inhibitors naproxen
and ibuprofen, has been reported in neonatal ventricular
myocytes.[43] However, given that the afore-mentioned study
was meant to investigate the effects of diclofenac on Ca2+
channels (see section on Ca2+ channels below), not much
detail is known about this action on INa. We therefore used
whole-cell patch-clamp measurements in isolated adult
ventricular myocytes (as described in Gwanyanya et al.[69])
to further evaluate the effects of diclofenac on INa. Figure 1b
shows that diclofenac (100 mm) suppressed INa activated
during a depolarizing voltage ramp protocol. Similar effects
can be obtainedwith the structurally related, but functionally
different drugs flufenamic acid (also a COX inhibitor) and
N-(p-amylcinnamoyl)anthranilic acid (ACA, a phospholi-
pase A2 inhibitor) (Figure 1b): like diclofenac, flufenamic
acid (100 mm) or ACA (20 mm) each inhibited INa and the
effects were reversible upon drug washout. Figure 3a illus-
trates the diclofenac effect on INa induced by a depolarizing
voltage step protocol, whereas Figure 3b shows that the drug
decreased the action potential duration and the rate of
maximal depolarization during the upstroke (Figure 3b,
lower panel), without affecting the resting potential.We also
observed a decrease of the action potential overshoot ampli-
tude (not illustrated; but see Macianskiene et al.[59]). These
effects are all consistent with a decrease of INa. Previously, we
reported that ACA, like diclofenac, reduced peak amplitudes
of ventricular action potentials, an effect consistent with the
block of INa reported here.[59] The above results indicated that,
like neuronal NaV channels, cardiac NaV channels were also
sensitive to a direct action of diclofenac and of fenamate
NSAIDs.
Voltage-gated Ca2+ channels
Currently, not much is known about the effects of NSAIDs,
including diclofenac, on voltage-dependent Ca2+ channels.
Salicylate inhibited ICa in rat pyramidal or inferior colliculus
neurons.[62,70] In those cells, the drug shifted the steady-state
inactivation curve to the left and delayed the recovery from
inactivation.
In a study involving rat neonatal ventricular myocytes,
diclofenac has been reported to suppress whole-cell L-type
Ca2+ currents (ICa-L) for which Ba2+ was the charge carrier.[43]
Those authors proposed that the reported diclofenac effects
were independent of COX inhibition, based on the lack of an
effect of naproxen or ibuprofen on ICa-L or on INa observed in
their preliminary experiments. The decrease of the Ba2+-
mediated ICa-L obtained in the presence of diclofenac was irre-
versible, but the reason for this irreversibility in the presence
of a reversible effect on INa remains unclear. It cannot be
excluded that the observed decrease of ICa-L was simply due
to run-down of the current and not to a pharmacological
effect, since no clear control of the kinetics of run-down
with or without diclofenac was mentioned in the study.
Nonetheless, in contrast to the effects in neonatal cardiac
myocytes, diclofenac has no effect on depolarization-
induced Ca2+ influx or on ICa-L in vascular smooth muscle
cells, probably depicting tissue-specific differences in the
10 ms
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Figure 3 Suppression of the voltage-gated Na+ current and effects
on action potential and on the rate of initial depolarization in cardiac
myocytes. (a) Traces of voltage-dependent Na+ currents (INa) induced at
-30 mV from a holding potential of -120 mV, in control conditions and
in the presence of increasing concentration of diclofenac. Cell dialysed
with physiological internal solution and superfused with Na+-containing
solution. The lower panel shows the voltage step protocol. Notice sup-
pression of INa by diclofenac. (b) Action potentials (upper panel) and their
first time derivatives (lower panels), recorded before (open circle) and
during application (solid circle) of diclofenac (100 mM). Ruptured-patch,
whole-cell recording. K+ used in both internal and external solutions.
Notice the decrease of action potential duration and the slowing of the
rate of upstroke.
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drug sensitivity.[44,71] Clearly, more studies are needed to
clarify the issue of the effect of diclofenac on ICa-L in cardi-
omyocytes and the potential contribution of an eventual
effect to the observed shortening of action potential.
K+ channels
Voltage-gated K+ channels
NSAIDs modulate a variety of natively- or heterologously-
expressed voltage-gated K+ channels. For diclofenac, the sen-
sitive channels include KV1.3 channels, transient outward
(IA or KV4.x) K+ channels and muscarinic receptor-inhibited
(M-type or KV7.2/3) K+ channels.[45–47,55,72] However, other
voltage-gated K+ channels such as KV1.2, KV1.5, and KV2.1
channels are unaffected by diclofenac.[45,46]
KV1.x and KV2.x currents
The NSAIDs indometacin, phenylbutazone and NS 398, but
not theCOX-1 selective inhibitor SC 560,decrease the surface
expression of heteromeric KV1.4 and KV1.6 channels in intes-
tinal epithelial cells.[73] Celecoxib, but not rofecoxib, inhibits
KV1.5 channels (as well as KV4.3 and KV7.1 channels)
expressed in mammalian cells and alters action potential
durations of ventricular myocytes.[74] Celecoxib also inhi-
bits heterologously-expressed KV2.x channels and induces
arrhythmias in rat ventricular myocytes.[75] In contrast, ace-
tylsalicylic acid (aspirin) does not have similar effects in the
same type of cells. However, salicylate inhibits the delayed
rectifier current in rat pyramidal cortical neurons by shifting
the steady-state inactivation to more negative potentials.[62]
Diclofenac has been reported to suppress both KV1.3 cur-
rents and channel protein expression as well as to alter the cell
migration patterns in leucocytes.[45] In that study, diclofenac
inhibited whole-cell KV1.3 currents in activated macro-
phages, decreased the interleukin-2 production in activated
T-lymphocytes, and downregulated the KV1.3 mRNA and
protein expression. Functionally, the drug impairs themigra-
tion of activated macrophages, an effect of diclofenac previ-
ously reported for other leucocytes.[45,76–78] The mechanisms
underlying the KV1.3 channel-mediated drug actions remain
unclear, but may involve the downregulation of stress signal
sensors like the inducible nitric oxide synthase (iNOS).[45]
Those authors have proposed that anti-inflammatory
actions of the drugmay include a component due to immune
modulation.
KV4.x currents
A fast transient outward current is present in neuronal
cells and is carried byKV4 channels. Similar transient outward
currents are present in other tissues, including cardiac cells,
where the underlying channel types and expression levels
are species-dependent but may involve KV4.x channels (see
Amuzescu et al.[79]).
Little is known about the effect of most NSAIDs on KV4
channels. Diclofenac increases the amplitude of the fast tran-
sient outward (IA or KV4.x) K+ currents in cerebellar granule
neurons.[47] The drug was efficacious when applied extracel-
lularly or intracellulary (via cell-dialysing pipette solutions).
The two effects were additive, suggesting that they involved
different mechanisms. The mechanisms underlying the
observed current increase remain unclear, since the drug had
no effect on the steady-state voltage-dependent activation,
while it shifted the steady-state inactivation curve to more
negative potentials. The latter effect is expected to cause a
decrease rather than the observed increase in peak current
amplitude. Diclofenac also caused a slight acceleration of
the recovery from inactivation, but this effect was unable to
account for the observed increase in current amplitude,
which was obtained with interpulse intervals (10 s) many
orders of magnitude longer than the time constants of resti-
tution (<10 ms). Either a prolongation of the channel open
time or an increase in single channel conductance could
account for the stimulatory effect on the transient outward
current. The former was suggested by the apparent slowing of
the current decay observed from the original current tracings.
However, no quantitative analysis of the time constants of
current decay was provided. It was unlikely that the stimula-
tory effect involved an increase in the total number of chan-
nels given the very fast time course of onset and offset of the
effect upon drug application and washout, respectively.
The transient outward current is proposed to have a role in
modulating neuronal excitability, but the diclofenac concen-
trations needed to modulate this current (10-5 m) are likely
too high to be therapeutically relevant.[47]
KV7 currents
Native muscarinic receptor-inhibited (M-type) K+ currents
in neurons are known to modulate neuronal excitability and
are carried by KV7.2/3 or KCNQ2/3 channels.[80] Diclofenac
and meclofenamic acid have been shown to cause a voltage-
dependent increase in the amplitude of whole-cell currents
carried by KV7.2/3 channels heterologously expressed in
Chinese hamster ovary (CHO) cells.[46] Diclofenac opens KV7
channels in the mouse olfactory bulb.[81] The drug effects in
CHO cells are due to a concentration-dependent shift of the
steady-state voltage-dependent activation to more negative
potentials, and are associated with a slowing of the rate of
deactivation upon repolarization following the activating
depolarization.[46] Similar effects are obtained with channels
heterologously expressed in Xenopus oocytes and with native
M current present in rat cortical neurons. As a result, hyper-
polarization of the resting membrane potential is induced
by diclofenac in Xenopus oocytes as well as in rat cortical
neurons, and in addition a suppression of spontaneous action
potentials is obtained in the neurons.[46] It is unclear why
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diclofenac and meclofenamic acid could produce prominent
effects on KV7.x channels, whereas other NSAIDs of the
fenamates group, such as flufenamic, mefenamic, tolfenamic
and niflumic acids, had no marked activating effects.[46]
Differences could be due to various potencies or to subtle
molecular structural differences. In any case, this finding
again indicated the presence of non-COX-mediated mecha-
nisms of action.
Voltage-gated KV7.4/5 (KCNQ4/5) K+ channels are also
expressed in vascular smooth muscles, where they are
involved in the control of vascular tone.[82] At lower concen-
trations (10 mm), diclofenac had no effect on KV7.5 current in
vascular smooth muscle cells.[44] In contrast, at 100 mm the
drug suppressed the KV7.5 current, and at the same time
enhanced the KV7.4 currents.[48] Mutation of residues in the
voltage-gating sensor of KV7.5 did not remove the blocking
properties of diclofenac, hence the site of action of the drug
on KV7.5 channels remains unclear.[48] The KV7.5 channel
inhibitory effect of diclofenac is also not a common feature of
NSAIDs or a reflection of their COX selectivity, since the
COX-2-selectiveNSAID rofecoxib hadno blocking effect, but
celecoxib inhibited the channels even more potently than
diclofenac.[44,83]
Ligand-gated K+ channels
A large body of indirect evidence from behavioural studies in
animal models of pain supports a possible role of diclofenac
as an opener of ligand-gated K+ channels like ATP-sensitive
K+ (KATP) and Ca2+-activated K+ (K(Ca)) channels.[49–54] The
opening of KATP channels has been proposed to mediate the
peripheral (i.e. at primary afferent neuron level) or central
(i.e. at spinal level) antinociceptive effects of diclofenac in
rat models of PGE2-mediated hyperalgesia and formalin-
induced pain.[49,51–54,84] Hence, the sulfonylurea drug, glib-
enclamide, which blocks KATP channels, also suppressed the
analgesic action of diclofenac in rats injected subcutaneously
with formalin.[51–53] In addition, the concurrent activation
of large conductance Ca2+-activated (BK(Ca)) and small con-
ductance Ca2+-activated (sK(Ca)) by diclofenac is implicated
in antinociceptive effects.[51,84]
ATP-sensitive channels
There is no direct evidence, such as can be derived from
voltage clamp studies, of an effect of diclofenac on KATP chan-
nels. As stated above, evidence that NSAIDs may act on these
channels is only indirect and derived from functional studies
measuring responses such as nociception and vasodilatation,
which are affected by activators and blockers of KATP channels.
KATP channels affect the excitability of neuronal cells and
their modulation by various physiological and pathological
factors may therefore interfere with various sensory mecha-
nisms, including nociception. KATP channels can be activated
by nitric oxide (NO), which can act on the channels either
indirectly via a pathway involving the production of cGMP
and the activation of protein kinase G, or directly via a
nitrosylation of the channel proteins.[85,86] The diclofenac
mode of action on the ligand-gatedK+ channels has been pro-
posed to involve nitric oxide synthase (NOS) and cGMP, since
the antinociceptive effects are prevented by inhibitors of NOS
or of guanylate cyclase.[49–52,54] Diclofenac also has synergistic
actions on peripheral antinociceptive effects of sildenafil, a
known inhibitor of cGMP-specific phosphodiestrases.[87,88]
Interestingly, the NOS-mediated central and peripheral
antinociceptive effects of diclofenac can be additive.[52] The
antinociceptive effects of ketorolac are also proposed to be
mediated by the NO-cGMP pathway.[89]
The mechanism underlying the diclofenac or ketorolac
effect on the NO-cGMP-PKG pathway remains unclear.
In cerebral vessels, diclofenac inhibits the hypercapnia-
and acid-induced upregulation of endothelial NOS (eNOS)
mRNA expression.[90] Regarding other possible mechanisms
of action, COX inhibition does not seem to be critical in
mediating peripheral antinociceptive effects as indometacin
is only effective in some pain models but not others.[49,51,54,84]
The role of opioid receptors in mediating the diclofenac
antinociceptive effects is also unclear. The central antinocice-
ptive effects of diclofenac are known to be reversed by the
opioid receptor antagonist naloxone, but naloxone has no
effect on diclofenac-induced peripheral antinociceptive
effects.[28,49,54]
In the above-mentioned pain models, the diclofenac anti-
nociceptive effects were attributed to K+ channel opening
mainly on the basis of the reversal of effects by specific
channel inhibitors e.g. by glibenclamide. A potential draw-
back of such extrapolations is that the target-specificities of
the inhibitors in vivo are not well-known. For example, drugs
like glibenclamide may, as expected, induce hypoglycaemia,
thereby creating potentially confounding factors, not neces-
sarily linked to the KATP channels in nociceptors. Further-
more, in one study involving human skin blood vessels,
diclofenac (which is proposed to promote K+ channel
opening in nociceptors) could not oppose the effects of
the KATP channel inhibitor glibenclamide in decreasing
acetylcholine-stimulated vasodilatation.[91] There is, there-
fore, still a need for direct electrophysiological characteriza-
tion of the effects on ATP-sensitive K+ channels.
Ca2+-activated and Na+-activated channels
Just like in the case of KATP channels, there is very little direct
voltage clamp evidence of an effect of NSAIDs on Ca2+-
sensitive K+ channels. Blockers of Ca2+-sensitive K+ channels
such as charybdotoxin and apamin, when administered
locally or intrathecally, abolished the antinociceptive effect of
diclofenac or of the structurally related COX-2 antagonist
Diclofenac and ion channels Asfree Gwanyanya et al.
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lumiracoxib.[92] The fenamates niflumic acid, meclofenamic
acid and tolfenamic acid stimulated large-conductance Ca2+-
sensitive K+ channels in osteoblast-like cells by shifting the
activation curve to hyperpolarized potentials.[93] In contrast,
piroxicam and NS 398 did not have similar effects.
Na+-sensitive K+ (Slo2.1) channels are related to Ca2+-
sensitive K+ channels and are activated by an increase of
intracellular Na+ concentration, as well as an increase
of intracellular Cl- or a decrease of intracellular ATP.[94]
Niflumic acid and flufenamic acid are strong activators of
the channels.[94]
Acid-sensing ion channels (ASICs)
Acid-sensing ismediated by capsacin-insensitive- (ASIC) and
by capsaicin-sensitive (TRPV1) channels. ASICs play an
important role in sensing of pain associated with inflamma-
tion. Their number is increased during inflammation in
neurons expressing them under basal conditions, and novel
expression appears in neurons not initially harbouring
them.[36] In addition, their activationmay contribute to other
types of cellular injury, for example during ischaemia.[95]
Various isoforms of ASICs exist and are probably differently
expressed in various cells.
NSAIDs such as salicylic acid, ibuprofen and diclofenac
have been shown to inhibit ASICs in nociceptors and in corti-
cal neuronal cells as well as in bone-marrow-derived den-
dritic cells.[36,57,95] The effects of salicylic acid were obtained
at clinically-relevant concentrations, indicating that these
effects may contribute to the analgesic and cell protection
action of the NSAID. The inhibitory actions of the various
drugs in nociceptors was accompanied with a suppression of
excitability, and in cultures of cortical neurons it resulted in
decreased lactate dehydrogenase release during cell incuba-
tion in acid medium, reflecting decreased acid-induced
cell damage. Those results may help explain antinociceptive
actions of NSAIDs persisting in COX-knock-out animals,
and the effects of aspirinmay contribute to its clinical useful-
ness during brain ischaemia following stroke. NSAIDs
such as piroxicam, tolmetin, etodolac, nimesulide, naproxen,
indometacin or paracetamol (acetaminophen) have no effect
on ASIC1a or ASIC3 activity.[36] Among the other NSAIDs,
flurbiprofen inhibits acid-mediated intracellular Ca2+
increase in rat brain cells, an effect that may account for the
drug’s cerebral tissue protection observed during ischaemia/
reperfusion.[96]
Diclofenac has a variety of effects on ASICs, including
changes in the properties of ASIC currents (IASIC),modulation
of proton sensitivity, and changes in protein expression. The
drug suppresses endogenous IASIC in hippocampal interneu-
rons and in bone marrow-derived dendritic cells, as well as
currents due to heterologously-expressed channels in COS or
CHO cells.[36,56,57] In hippocampal interneurons, diclofenac
does not compete with protons since the activating half-
maximum pH is unchanged.[56] The effect of diclofenac is
voltage-independent, in contrast with the effect of inhibitors
such as amiloride, which displays voltage-dependence. Its
blocking effect is attenuated in the absence Ca2+, suggesting
possible interactions between protons, the divalent cation
and the drug.[56] In addition to decreasing the current ampli-
tude, there is a slowing of the time course of IASIC decay.
Diclofenac alters the pH-sensitivity of the desensitization
process, which occurs at more alkaline pH, and slows the
recovery from desensitization while having no significant
effect on the time course of onset of desensitization.[56] In het-
erologous expression systems, diclofenac suppresses currents
due toASIC1a/2a,ASIC2a, andASIC3 channels in CHO cells,
and onlyASIC3 currents in COS cells, but the explanation for
this difference is unclear since the same channel isoform was
expressed.[36,56] One possible explanation is the difference in
diclofenac concentrations tested in the two studies (lower in
the study of COS cells) but the expression system itself may
possibly have an influence on the concentration–response
relationship. The inhibitory effects of diclofenac on ASIC3 in
COS cells and ASIC in hippocampal interneurons are likely
to be independent of COX inhibition, given that not all
NSAIDs tested had inhibitory effects on the currents.[36,56]
Apart from the actions on ASIC activity, diclofenac inhibits
the inflammation-induced mRNA expression of ASIC in
DRG neurons.[36] In dendritic cells, the drug prevents the
acid-induced upregulation of cell surface markers that are
normally associated with cell maturation.[57]
It is interesting to note the homology between the voltage-
dependent inactivation of NaV channels and the desensitiza-
tion of ASIC currents. Both result in the slow decline of
current but are induced by different factors, transmembrane
voltage or protons, respectively. For ASIC, acidification is
equivalent to depolarization, and the more alkaline the pH
the more ASIC channels are available. Similar to the effect
on voltage-dependent channels where channel availability is
decreased by diclofenac (half-maximum inactivating voltage
shifted to more negative potentials), for ASIC, channel avail-
ability is also decreased (half-maximum inactivating pH
shifted to higher pH values) by the drug. The slowed decay of
IASIC despite increased extent and unaltered kinetics of onset
of desensitization could possibly be explained by a delayed
and/or prolonged opening of the channels during acidifica-
tion. This would account for the observed slowing of IASIC
decay by ibuprofen, despite it having no effect on inactiva-
tion, and for the increased time to peak current.[56]
Functionally, the inhibitory effects of diclofenac on ASICs
may partly account for the decrease in CO2-evoked responses
seen in corneal polymodal nociceptors.[42] The drug effects
may alsomediate themodulation of acid-induced pain trans-
duction observed in humans since topical application of
the drug decreases such type of pain.[97] However, in airway
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10
tissue, diclofenac has no effect on the acid-induced tracheal
ring relaxation likely to be mediated by ASICs.[98]
Transient receptor potential and other channels
Transient receptor potential (TRP) channels are a new group
of cation channels found in several tissues and are involved in
mediating sensory signalling and various other physiological
and disease processes.[99] The effects of NSAIDs on TRPs and
related channels are increasingly being studied.
TRPs include the ankyrin 1 subgroup (TRPA1) channels
(previously known as ANKTM1), which are temperature
(cold)-sensitive and are particularly expressed in nociceptor
neurons.[100] Fenamate NSAIDs (such as flufenamic acid,
niflumic acid), diclofenac and indometacin activate TRPA1
channels heterologously expressed in Xenopus oocytes and
promote TRPA1-mediatedCa2+ loading in lung fibroblasts.[58]
Other NSAIDs like naproxen and ketorolac are ineffective,
suggesting COX-independent mechanisms.[58] Instead, given
that flufenamic acid amplified the stimulatory actions of cold
temperature, allosteric actions or synergistic interactions
among the TRPA1 channel activators may play a role.[58]
A recent study investigated the effect of diclofenac and ibu-
profen on TRPC6 channel activity recorded using the cell-
attached patch method in podocytes of freshly isolated
glomeruli and showed that both drugs decreased the open
probability of the channel.[101] The single channel conduc-
tance was not modified by the drugs. Gain-of-function
mutations of TRPC6 are associated with focal segmental
glomerulosclerosis, probably due to a dysfunction of podo-
cytes, and NSAIDs have been reported to have beneficial
action in this condition. It is therefore likely that the NSAID
effect on TRPC6 could mediate this beneficial effect.
However, since only one drug concentration (500 mm) was
used in the above study,moreworkwill be needed to establish
the concentration–response relationship and clarify its rel-
evance to therapeutic concentrations. It remains unclear
whether the observed effect was related to COX inhibition.
Diclofenac is reported to have no effect on capsaicin-
induced (i.e. TRPV1-mediated) relaxant effect on ileum
smooth muscles.[102] Since neuronal TRPV1 is implicated in
thermo-sensing and in acid-sensing, the modulation of these
sensations by diclofenac, as in the case for acid-sensing,
implies the involvement of additional receptors in the sensing
function (e.g. implication of both TRPV1 andASIC channels
in acid-sensing). In mice, pretreatment with diclofenac
had no effect on menthol-induced (i.e. TRPM8-mediated)
hyperthermia.[103] It is doubtful whether the NSAID effect
on TRPA1 represents a common feature of the drugs on
temperature-sensitive TRPs given that NSAIDs containing
the anthranilic acid ring inhibit rather than stimulate the
thermosensitive channels TRPV1, TRPV3 and TRPM8.[58]
Flufenamic acid inhibits other TRPs like TRPC3, TRPC5,
TRPC7, TRPM2, and TRPM4 channels (see Clapham[104])
and activates TRPC6 channels.[105] Although diclofenac and
flufenamic acid are structurally related considering that
they both contain a core phenyl-amino-phenyl ring, it is not
uncommon for them to display different effects on the same
type of channel. In a recent study, we showed that flufenamic
acid and the related drug ACA were able to induce a cation
nonselective current in cardiac ventricularmyocytes,whereas
diclofenac was ineffective.[59]
In erythrocytes, diclofenac is proposed to modulate
apoptotic cell death by inhibiting a stress-activated Ca2+-
permeable channel, thereby preventing Ca2+ overload.[60,106]
The drug suppresses whole-cell cation currents induced by
the removal of extracellular chloride or by PGE2 and
decreases intracellular Ca2+ accumulation.[60,106] The channels
appear to be linked toCa2+ signalling processes as the currents
and theCa2+ loading are greater inmice deficient in annexin, a
Ca2+-binding regulator protein.[106] Diclofenac is proposed to
act partly via the inhibition of COX, since PGE2 is involved
and the above-mentioned effects are inhibited by aspi-
rin.[60,106] The drug effects may affect other arachidonic
acid metabolites, given that inhibition of lipoxygenase
enhances the PGE2-induced channel activity and that these
lipoxygenase-mediated effects are sensitive to diclofenac.[107]
In rodent melanoma cells, diclofenac increases the ampli-
tude of a Ca2+-regulated K+ current. The current is inhibited
instead of being activated by intracellular Ca2+, and the
underlying channels were proposed to belong to the EAG
family of channels and to be implicated in cell migration.[55]
However, the nature of the channels remains uncertain since
the observed currents could be due to other channel types
that are activated under similar conditions. TRPM7 channels
are sensitive to intracellular divalent cations and, although
they are nonselective, they carry outward K+ currents at posi-
tive potentials (seeGwanyanya et al.[69,108] andKozak et al.[109]).
The possibility that the Ca2+-sensitive currents recorded in
melanoma cells are carried by TRPM7 channels needs to be
considered given the expression of TRPM7 and its role in
survival in these cells.[110] The mode of action of diclofenac
in the melanoma cells may involve modulation of endo-
thelin receptors (ETC), since diclofenac reverses both the
endothelin 1-induced decrease in the K+ current and the
endothelin 1-associated decrease in cell migration.[55]
Various NSAIDs, including salicylate, ibuprofen, sulin-
dac, and indometacin all inhibit store-operated Ca2+ entry
(SOCE) in smoothmuscle (without affecting depolarization-
induced Ca2+ entry due to the opening of voltage-
sensitive Ca2+ channels). Similar effects are obtained with
R-flurbiprofen, which has no anti-inflammatory action, sug-
gesting a dissociation of this effect from COX inhibition.
SOCE is mediated by so-called Ca2+-release activated Ca2+
(CRAC) channels in association with Orai. However, it has
been shown that the NSAIDs do not directly inhibit the
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current carried by the CRAC channels (ICRAC) but do so by
preventing mitochondria from taking up Ca2+ (hence
enhancing Ca2+-dependent inactivation). This inhibitory
action on SOCE seems to be associated with an antiproli-
ferative action.[71]
Anion channels
TheNSAID ibruprofen improves symptoms in cystic fibrosis,
a disease due to mutations in the cAMP-gated, Cl- selective
cystic fibrosis transmembrane conductance regulator
(CFTR) channels. Earlier studies indicated that ibuprofen
(and also salicylate and aspirin, both at much higher concen-
trations) inhibited CFTR channels (by apparently reducing
single channel conductance) in respiratory epithelial cells.[111]
Ibuprofen inhibits CFTR-mediated Cl- secretion, a result
which cannot account for the beneficial effect of this drug in
cystic fibrosis but which instead would predict aggravation.
Similarly, aspirin, indometacin and ibuprofen decreased the
CFTRgene expression and suppressed cAMP-stimulated cur-
rents in carcinoma cells.[112] However, the effect of NSAIDs
may depend on the basal stimulation of the channel. In
human epithelial cells ibuprofen either suppresses or stimu-
lates CFTR Cl- currents depending on the concentration
of intracellular cAMP.[113] Under high cAMP stimulation
levels, ibuprofen inhibits the channel in a voltage-dependent
manner, since inhibition is higher at negative potentials. This
inhibitory effect is mediated from the extracellular side of the
membrane andmay involve channel occlusion. In contrast, at
low cAMP-mediated stimulation or under perforated patch
recording conditions (which minimize perturbations of the
intracellular medium) ibuprofen enhances CFTR currents.
Similar effects could be obtained with meflofenamic acid.
Interestingly, the stimulatory effect was obtained at clinically
relevant concentrations (5 mm), whereas much higher con-
centrations were needed for the inhibitory action. While
this stimulatory action of NSAIDs on CFTR functionmay be
beneficial, a decrease of the expression of the channels by
the same drugs may at least partly counteract the beneficial
effect.[112]
Fenamate drugs such as flufenamic acid are known to
inhibit variousCl- currents, and so diclofenac,which presents
some similarity with these drugs, could be expected to block
these currents. However, we found that diclofenac did not
inhibit the Ca2+-activated Cl--based transient outward
current in cardiac ventricular myocytes, even in cells where
the current could be suppressed by flufenamic acid or by
ACA.[114] Similarly, diclofenac did not inhibit the GABA-
induced activation of Cl- currents in sensory neurons, in con-
trast to other NSAIDs such as indometacin or ibuprofen-like
drugs.[115] The co-administration of these latter NSAIDs
enhanced the convulsive potency of drugs such as quinolone-
based antibiotics, an effect related to the inhibition of the
binding of GABA to its receptor. Therefore, diclofenac
appears safer in combined therapy with these antibiotics.
Therapeutic and toxicological
implications
Drug effects
The drug actions on ion channels outlined above may
account for several therapeutic or adverse effects not directly
linked to classic NSAID actions. On the one hand, NSAIDs
may have short-term beneficial effects such as peripheral and
central analgesia, regulation of cell excitability and possibly
anticonvulsant activity. In addition, by limiting Ca2+ influx
and the associated cell damage, the drugs may afford cellular
protection.The effect on Ca2+ influx can also influence vascu-
lar tone. The intermediate- to long-term effects arising from
transcriptional modifications and alterations in protein syn-
thesis includemodulation of apoptosis and of inflammation-
induced immune responses, as well as modulation of cell
proliferation and of cell migratory patterns. On the other
hand, possible adverse effects include neurological dysfunc-
tion or cardiac arrhythmogenesis due to excessive inhibition
of Na+ and Ca2+ channels.
For the more extensively studied NSAID diclofenac, a key
question is whether the effects on ion channels are expected
to occur under therapeutic conditions. Given that the IC50
value of diclofenac for COX-1 inhibition is 0.2 mm, whereas
that for COX-2 is 0.6 mm, and given that the peak plasma con-
centrations of the drug under clinical conditions can be
approximately 5–10 mm,most of the therapeutic effects could
be attributed to COX inhibition.[116–118] In many studies, the
doses of diclofenac needed in vivo to modulate ion channels
are high, e.g. 18 mg/kg (approximately 90 mm) to induce
antinociceptive effects in rats and an ED50 value of 43 mg/kg
(approximately 200 mm) for anticonvulsant effects in
mice.[46,53] While most of the effects on ion channels seem to
occur at nontherapeutic concentrations, those on some neu-
ronal andmyoblastNa+ channels (Kd = 7–14 mm) aswell as on
leucocyte KV1.3 channels (Kd = 2.6 mm) occur at concentra-
tions compatible with a clinical effect (see Table 1). Higher
local concentrations can be obtained following topical (e.g.
skin) applications and could induce local COX-independent
effects. In addition, the drug is also highly bound to proteins
and undergoes hepatic first-pass metabolism, suggesting that
the effective drug concentration could be overestimated
when calculated on the basis of the total drug dose adminis-
tered in in-vivo studies.[117] Furthermore, for synergistic
effects with other drugs or for changes in gene expression,
minimal concentrations may suffice. As an example, as dis-
cussed earlier, diclofenac potentiates the effect of ineffective
concentrations of sildenafil in inducing antinociceptive
effects.[87] Finally, for many of the channels, the effective
concentrations of diclofenac have not been determined yet.
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The mechanisms underlying the NSAID effects on ion
channels are diverse (see Figure 2), and in most cases appear
to be independent of COX inhibition.[66,67,119] One such
mechanism of action involves direct drug binding to induce
block, to induce allosteric effects, or to produce synergistic
or antagonistic actions with other channel modulators. This
appears to be the case with voltage-gated Na+, voltage-gated
L-type Ca2+, some voltage-gated K+, ASICs, TRPs and other
nonselective cation channels. Secondly, diclofenac may indi-
rectly affect channels by interacting with the production of
second messengers like NO and cGMP as is probably the
case for ligand-gated K+ channels. Thirdly, the modulation
of the expression of channel proteins and of regulatory mol-
ecules may play a role in KV channels, ASICs and Ca2+-
regulated K+ channels. For some channels, however, there
may be cross-talk between COX inhibition and the other
NSAID effects. This may be the case for stress-activated
Ca2+-permeable channels in erythrocytes, where the chan-
nels are sensitive to a drug like diclofenac but can also be
activated by PGE2, a downstream metabolite of COX activ-
ity.[60,106] The same could apply to channels like KV1.3 and
ASICs.[36,45]
Contribution of channel effects to the
anticonvulsive and antalgic actions
Functionally, it has been proposed that the local anaesthetic-
like, INa blocking, actions of diclofenac in neurons may
account for its suppression of mechanically-stimulated
pain in masseter muscle nociceptors.[120] In addition, topical
application of the drug decreases noxious stimuli-evoked
responses in corneal polymodal nociceptors.[42]
Diclofenac shares the same effect on neuronal channels
with carbamazepine and with local anaesthetics, and at
the same time is able to activate KV7 channels, and so the
drug may be expected to have anticonvulsive action. Its
affinity of binding on Na+ channels is even higher than
that of carbamazepine, suggesting that at doses given
clinically (1–2 mg/kg) it may be more active than carbam-
azepine. Indeed, diclofenac has been shown to have anticon-
vulsant activity in mice, but so far the contribution of
the INa inhibition to this effect is not known, and the anti-
convulsive effect has been attributed only to the activation
of K+ channels.[46] Diclofenac suppresses spontaneous or
evoked cortical neuron activity and has anticonvulsant
activity in mice, as assessed using electroshock tests, but the
effects have not yet been linked directly to the activity of
M-type K+ channels.[46] Nonetheless, for these anticonvul-
sant effects of diclofenac, certain structural components of
the drug seem to be important. For example, its ester deriva-
tive (named compound 15) shows anticonvulsant effects,
whereas the amide derivative (named compound 6) has
none.[72]
Future directions
Considering the ill fate of COX-2-selective NSAIDs like rofe-
coxib, the key to the continued clinical use of NSAIDs is likely
to depend on their cardiovascular safety profile. It is known
that several NSAIDs are associated with a high cardiovascular
risk.[19,20,32,121] As stated above, the cardiovascular morbidity
of COX-2-selective drugs has tentatively been attributed to
atherogenic effects (see Joshi et al.[23]). The expression of
COX-2 is also known to be important in the cardioprotection
produced by ischaemic or pharmacological precondi-
tioning.[122,123] However, diclofenac and other nonselective
NSAIDs still cause long-term cardiovascular morbidity at
levels as high as those of COX-2-selective drugs.[121] Thus, the
cardiovascular adverse effects of NSAIDs require further elu-
cidation. In the liver,diclofenac induces hepatotoxicity via the
opening of a channel-like structure in the mitochondrial
innermembrane called themitochondrial permeability tran-
sition pore, a pathway of entry of lethal substances into the
mitochondria during oxidative stress.[124,125] Such a pore is
present in cardiac cells, where its closure during ischaemia is
known to promote cardioprotection via the process of
ischaemic preconditioning.[126,127] Currently, the effect of
diclofenac on themitochondrial permeability transition pore
in the heart is not known. As for conventional cardiac chan-
nels, we have shown here that diclofenac and fenamates
inhibited cardiac Na+ channels (see Yarishkin et al.[43]). Also,
we have shown here, as well as in previous studies, that the
drugs decreased the amplitude and shortened the duration
of ventricular action potentials.[59] This effect is similar to
that of local anaesthetics and as such may, to some extent,
be anti-arrhythmic. However, pro-arrhythmic actions may
result from excessive changes. Taken together with the
likelihood that diclofenac and other NSAIDs could inhibit
cardiac Ca2+ channels and KV channels, this may account
for increased cardiac mortality if arrhythmias and cardiac
contractile dysfunction are induced.[43,75]
As mentioned above, some effects of diclofenac can be
attributed to specific structural components present in other
drugs (Figure 1a). So far, some derivatives of diclofenac have
already been shown to exhibit differences in COX-inhibiting
activity or in inducing anticonvulsant effects as well as to have
substantial antimycobacterial activity.[72,128] The drug may
therefore serve as a template for the development of new ion
channel modulators that are in the form of nonselective
NSAIDs.
Conclusions
Several NSAIDs have therapeutic and adverse effects (includ-
ing cardiovascular morbidity), some of which may be due to
their actions on ion channels. Many of these effects of ion
channels are unrelated to COX inhibition and include drug–
channel interactions, the release of second messengers and
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changes in gene expression. As more knowledge of such
mechanisms of action becomes available, the NSAIDs’ thera-
peutic or adverse effects will become better understood.
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